{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:00:14Z","timestamp":1787583614626,"version":"build-2736575974"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment (R-ICHT). Methods: Thirty-one patients with PMBCL were recruited. After completion of R-ICHT, patients were staged with 18F-fluorodeoxyglucose positron-emission tomography, showing DS 4, and were treated with adjuvant RSRT. The chosen techniques for RT delivery were intensity-modulated radiation therapy (IMRT) or three-dimensional conformal RT (3D-CRT). Most patients underwent the first one using cone-beam computed tomography (CBCT). All patients were evaluated every 3 months for the first 2 years and every 6 months afterwards for a period of at least 5 years, with clinical and radiological procedures as required. Results: All patients received RSRT with a dose of 30 Gy in 15 fractions. The median follow-up time of 52.7 months (IQR: 26\u201364.1 months). The 5-year OS rate was 100%. The 2-year and 5-year PFS rates were 96.7% and 92.5%, respectively. Patients with relapsed disease had been treated with high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT). Conclusion: RSRT in patients with PMBCL treated with ICHT and DS 4 did not impact unfavorably on patient survival.<\/jats:p>","DOI":"10.3390\/jcm12113777","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T02:57:10Z","timestamp":1685501830000},"page":"3777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Giuseppe","family":"Facondo","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Serio","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2521-1088","authenticated-orcid":false,"given":"Gianluca","family":"Vullo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paola","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Hematology Institute, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Pelliccia","sequence":"additional","affiliation":[{"name":"Hematology Institute, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Umberto I, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Lanzolla","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-3005","authenticated-orcid":false,"given":"Maurizio","family":"Valeriani","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3159-5380","authenticated-orcid":false,"given":"Arianna","family":"Di Napoli","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Tafuri","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Umberto I, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Umberto I, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8996-5559","authenticated-orcid":false,"given":"Mattia Falchetto","family":"Osti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaliana","family":"De Sanctis","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"654854","DOI":"10.3389\/fonc.2021.654854","article-title":"Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.21873\/invivo.11921","article-title":"Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study","volume":"34","author":"Cox","year":"2020","journal-title":"In Vivo"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1586\/17474086.2015.994604","article-title":"Primary mediastinal lymphoma: Diagnosis and treatment options","volume":"8","author":"Martelli","year":"2015","journal-title":"Expert. Rev. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.15731","article-title":"The management of primary mediastinal B-cell lymphoma: A British Society for Haematology Good Practice Paper","volume":"185","author":"Cwynarski","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_6","unstructured":"National Comprehensive Cancer Network (2022). NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas, National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijrobp.2015.02.006","article-title":"Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Chen","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2016.02.057","article-title":"Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation","volume":"95","author":"Filippi","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2015.120","article-title":"PET\/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy","volume":"30","author":"Vassilakopoulos","year":"2016","journal-title":"Leukemia."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijrobp.2021.03.035","article-title":"Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria","volume":"111","author":"Hoppe","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","first-page":"131","article-title":"The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"2","author":"Hosein","year":"2010","journal-title":"Eur. J. Clin. Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2005-01-0272","article-title":"[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome","volume":"106","author":"Haioun","year":"2005","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3324\/haematol.10895","article-title":"Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma","volume":"92","author":"Dupuis","year":"2007","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2808","DOI":"10.1097\/MD.0000000000002808","article-title":"Predictive Significance of a New Prognostic Score for Patients with Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings","volume":"95","author":"Kong","year":"2016","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.semnuclmed.2022.09.001","article-title":"Modern PET-Guided Radiotherapy Planning and Treatment for Malignant Lymphoma","volume":"53","author":"Pepper","year":"2023","journal-title":"Semin. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2022.02.017","article-title":"Balancing the Therapeutic Ratio in DLBCL Requires Appropriate, Individualized Patient Selection Rather Than Broad Elimination of Radiation Therapy","volume":"113","author":"Campbell","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00066-022-02035-9","article-title":"The new German evidence-based guideline on diffuse large B-cell lymphoma-key aspects for radiation oncologists","volume":"199","author":"Oertel","year":"2023","journal-title":"Strahlenther. Onkol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10585-019-09992-z","article-title":"The prognostic value of PET\/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: A multi-institutional study of KROG 17-02","volume":"37","author":"Lee","year":"2020","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study","volume":"32","author":"Martelli","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijrobp.2013.05.053","article-title":"Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy","volume":"87","author":"Filippi","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2016.09.031","article-title":"Positron Emission Tomography\/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma","volume":"97","author":"Ceriani","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_25","unstructured":"Martelli, M. (2015, January 17\u201320). The IELSG-37 study: A randomized trial assessing the role of mediastinal radiotherapy after front-line rituximab and anthracycline containing regimens in patients with primary mediastinal B cell lymphoma (PMBCL). Proceedings of the 13th International Conference on Malignant Lymphoma 2015, Lugano, Switzerland."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2008.02.036","article-title":"MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma","volume":"72","author":"Finolezzi","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3816\/CLM.2009.n.074","article-title":"Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: A retrospective study","volume":"9","author":"Zinzani","year":"2009","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study","volume":"22","author":"Rieger","year":"2011","journal-title":"Ann. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:45:47Z","timestamp":1760125547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["jcm12113777"],"URL":"https:\/\/doi.org\/10.3390\/jcm12113777","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}